<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25833050</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.</ArticleTitle><Pagination><StartPage>6196</StartPage><EndPage>6208</EndPage><MedlinePgn>6196-208</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00422-15</ELocationID><Abstract><AbstractText Label="UNLABELLED">Human enterovirus 71 (EV71) and coxsackievirus A16 (CVA16) are the two major causative agents for hand-foot-and-mouth disease (HFMD). Previously, we demonstrated that a virus-like particle (VLP) for EV71 produced from Saccharomyces cerevisiae is a potential vaccine candidate against EV71 infection, and an EV71/CVA16 chimeric VLP can elicit protective immune responses against both virus infections. Here, we presented the crystal structures of both VLPs, showing that both the linear and conformational neutralization epitopes identified in EV71 are mostly preserved on both VLPs. The replacement of only 4 residues in the VP1 GH loop converted strongly negatively charged surface patches formed by portions of the SP70 epitope in EV71 VLP into a relatively neutral surface in the chimeric VLP, which likely accounted for the additional neutralization capability of the chimeric VLP against CVA16 infection. Such local variations in the amino acid sequences and the surface charge potential are also present in different types of polioviruses. In comparison to EV71 VLP, the chimeric VLP exhibits structural changes at the local site of amino acid replacement and the surface loops of all capsid proteins. This is consistent with the observation that the VP1 GH loop located near the pseudo-3-fold junction is involved in extensive interactions with other capsid regions. Furthermore, portions of VP0 and VP1 in EV71 VLP are at least transiently exposed, revealing the structural flexibility of the VLP. Together, our structural analysis provided insights into the structural basis of enterovirus neutralization and novel vaccine design against HFMD and other enterovirus-associated diseases.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Our previous studies demonstrated that the enterovirus 71 (EV71) virus-like particle (VLP) produced from yeast is a vaccine candidate against EV71 infection and that a chimeric EV71/coxsackievirus A16 (CVA16) VLP with the replacement of 4 amino acids in the VP1 GH loop can confer protection against both EV71 and CVA16 infections. This study reported the crystal structures of both the EV71 VLP and the chimeric EV71/CVA16 VLP and revealed that the major neutralization epitopes of EV71 are mostly preserved in both VLPs. In addition, the mutated VP1 GH loop in the chimeric VLP is well exposed on the particle surface and exhibits a surface charge potential different from that contributed by the original VP1 GH loop in EV71 VLP. Together, this study provided insights into the structural basis of enterovirus neutralization and evidence that the yeast-produced VLPs can be developed into novel vaccines against hand-foot-and-mouth disease (HFMD) and other enterovirus-associated diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015, American Society for Microbiology. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lyu</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Ya-Ling</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hao-Yang</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China rongchen@ips.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>4YVS</AccessionNumber><AccessionNumber>4YVW</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>12</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25833050</ArticleId><ArticleId IdType="pmc">PMC4474312</ArticleId><ArticleId IdType="doi">10.1128/JVI.00422-15</ArticleId><ArticleId IdType="pii">JVI.00422-15</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McMinn PC. 2012. Recent advances in the molecular epidemiology and control of human enterovirus 71 infection. Curr Opin Virol 2:199&#x2013;205. doi:10.1016/j.coviro.2012.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2012.02.009</ArticleId><ArticleId IdType="pubmed">22482716</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Ang RX, Alonso S, Chow VT, Quak SH, Poh CL. 2008. Identification of immunodominant VP1 linear epitope of enterovirus 71 (EV71) using synthetic peptides for detecting human anti-EV71 IgG antibodies in Western blots. Clin Microbiol Infect 14:286&#x2013;288. doi:10.1111/j.1469-0691.2007.01904.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2007.01904.x</ArticleId><ArticleId IdType="pubmed">18076666</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. 2007. Identification of neutralizing linear epitopes from the VP1 capsid protein of enterovirus 71 using synthetic peptides. Virus Res 125:61&#x2013;68. doi:10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk K, Poh CL, Fecondo J, Pourianfar H, Shaw J, Grollo L. 2012. Cross-reactive neutralizing antibody epitopes against enterovirus 71 identified by an in silico approach. Vaccine 30:7105&#x2013;7110. doi:10.1016/j.vaccine.2012.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.09.030</ArticleId><ArticleId IdType="pubmed">23022400</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, Sia C, Chong P. 2011. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine 29:4362&#x2013;4372. doi:10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Cifuente JO, Ashley RE, Conway JF, Makhov AM, Tano Y, Shimizu H, Nishimura Y, Hafenstein S. 2013. A strain-specific epitope of enterovirus 71 identified by cryo-electron microscopy of the complex with fab from neutralizing antibody. J Virol 87:11363&#x2013;11370. doi:10.1128/JVI.01926-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01926-13</ArticleId><ArticleId IdType="pmc">PMC3807339</ArticleId><ArticleId IdType="pubmed">23946455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener TK, Jia Q, Meng T, Chow VT, Kwang J. 2014. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved &#x201c;knob&#x201d; region of VP3 protein. PLoS Negl Trop Dis 8:e2895. doi:10.1371/journal.pntd.0002895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002895</ArticleId><ArticleId IdType="pmc">PMC4038473</ArticleId><ArticleId IdType="pubmed">24875055</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Huang X, Liu Q, Huang Z. 2013. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine 31:2130&#x2013;2136. doi:10.1016/j.vaccine.2013.02.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.02.051</ArticleId><ArticleId IdType="pubmed">23499595</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Han JF, Qin CF, Chen R. 2013. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31:3281&#x2013;3287. doi:10.1016/j.vaccine.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. 2012. Crystal structure of human enterovirus 71. Science 336:1274. doi:10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z. 2012. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19:424&#x2013;429. doi:10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K, Ding J, Han JF, Zhang Y, Wu XY, He YL, Qin CF, Chen R. 2014. Human enterovirus 71 uncoating captured at atomic resolution. J Virol 88:3114&#x2013;3126. doi:10.1128/JVI.03029-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03029-13</ArticleId><ArticleId IdType="pmc">PMC3957924</ArticleId><ArticleId IdType="pubmed">24352461</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Li HY, Han JF, Deng YQ, Zhu SY, Li XF, Yang HQ, Li YX, Zhang Y, Qin ED, Chen R, Qin CF. 2015. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice. Sci Rep 5:7878. doi:10.1038/srep07878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep07878</ArticleId><ArticleId IdType="pmc">PMC4297979</ArticleId><ArticleId IdType="pubmed">25597595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K, Wang GC, He YL, Han JF, Ye Q, Qin CF, Chen R. 2015. Crystal structures of enterovirus 71 (EV71) recombinant virus particles provide insights into vaccine design. J Biol Chem 290:3198&#x2013;3208. doi:10.1074/jbc.M114.624536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.624536</ArticleId><ArticleId IdType="pmc">PMC4318995</ArticleId><ArticleId IdType="pubmed">25492868</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L, Rossmann MG. 1997. Rotation function calculations with GLRF program. Methods Enzymol 276:594&#x2013;611. doi:10.1016/S0076-6879(97)76080-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0076-6879(97)76080-4</ArticleId><ArticleId IdType="pubmed">9048382</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66:213&#x2013;221. doi:10.1107/S0907444909052925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909052925</ArticleId><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486&#x2013;501. doi:10.1107/S0907444910007493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444910007493</ArticleId><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera&#x2014;a visualization system for exploratory research and analysis. J Comput Chem 25:1605&#x2013;1612. doi:10.1002/jcc.20084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20084</ArticleId><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong M, Zhu H, Zhou J, Yang C, Feng J, Huang X, Ji G, Xu H, Zhu P. 2014. Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development. J Virol 88:6444&#x2013;6452. doi:10.1128/JVI.00200-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00200-14</ArticleId><ArticleId IdType="pmc">PMC4093858</ArticleId><ArticleId IdType="pubmed">24672036</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD, Ferguson M, Katrak K, Wood D, John A, Howlett J, Dunn G, Burke K, Almond JW. 1991. Antigenic structure of chimeras of type 1 and type 3 polioviruses involving antigenic sites 2, 3 and 4. J Gen Virol 72:2475&#x2013;2481. doi:10.1099/0022-1317-72-10-2475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-72-10-2475</ArticleId><ArticleId IdType="pubmed">1717641</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta C, Kotecha A, Burman A, Jackson T, Ren J, Loureiro S, Jones IM, Fry EE, Stuart DI, Charleston B. 2013. Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen. PLoS Pathog 9:e1003255. doi:10.1371/journal.ppat.1003255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003255</ArticleId><ArticleId IdType="pmc">PMC3609824</ArticleId><ArticleId IdType="pubmed">23544011</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke KL, Dunn G, Ferguson M, Minor PD, Almond JW. 1988. Antigen chimaeras of poliovirus as potential new vaccines. Nature 332:81&#x2013;82. doi:10.1038/332081a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/332081a0</ArticleId><ArticleId IdType="pubmed">2450279</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin A, Wychowski C, Couderc T, Crainic R, Hogle J, Girard M. 1988. Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice. EMBO J 7:2839&#x2013;2847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC457076</ArticleId><ArticleId IdType="pubmed">2460345</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray MG, Kuhn RJ, Arita M, Kawamura N, Nomoto A, Wimmer E. 1988. Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys. Proc Natl Acad Sci U S A 85:3203&#x2013;3207. doi:10.1073/pnas.85.9.3203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.85.9.3203</ArticleId><ArticleId IdType="pmc">PMC280172</ArticleId><ArticleId IdType="pubmed">2834736</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DJ, McKeating J, Meredith JM, Burke KL, Katrak K, John A, Ferguson M, Minor PD, Weiss RA, Almond JW. 1989. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 339:385&#x2013;388. doi:10.1038/339385a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/339385a0</ArticleId><ArticleId IdType="pubmed">2542797</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins O, Cason J, Burke KL, Lunney D, Gillen A, Patel D, McCance DJ, Almond JW. 1990. An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16. J Virol 64:1201&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC249234</ArticleId><ArticleId IdType="pubmed">2154604</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T, Porta C, Lomonossoff G, Johnson JE. 1996. Structure-based design of peptide presentation on a viral surface: the crystal structure of a plant/animal virus chimera at 2.8 A resolution. Fold Des 1:179&#x2013;187. doi:10.1016/S1359-0278(96)00030-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-0278(96)00030-2</ArticleId><ArticleId IdType="pubmed">9079380</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeates TO, Jacobson DH, Martin A, Wychowski C, Girard M, Filman DJ, Hogle JM. 1991. Three-dimensional structure of a mouse-adapted type 2/type 1 poliovirus chimera. EMBO J 10:2331&#x2013;2341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC452928</ArticleId><ArticleId IdType="pubmed">1651227</ArticleId></ArticleIdList></Reference><Reference><Citation>Butan C, Filman DJ, Hogle JM. 2014. Cryo-electron microscopy reconstruction shows poliovirus 135S particles poised for membrane interaction and RNA release. J Virol 88:1758&#x2013;1770. doi:10.1128/JVI.01949-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01949-13</ArticleId><ArticleId IdType="pmc">PMC3911577</ArticleId><ArticleId IdType="pubmed">24257617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubeck D, Filman DJ, Cheng N, Steven AC, Hogle JM, Belnap DM. 2005. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol 79:7745&#x2013;7755. doi:10.1128/JVI.79.12.7745-7755.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.12.7745-7755.2005</ArticleId><ArticleId IdType="pmc">PMC1143686</ArticleId><ArticleId IdType="pubmed">15919927</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis JK, Bothner B, Smith TJ, Siuzdak G. 1998. Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A 95:6774&#x2013;6778. doi:10.1073/pnas.95.12.6774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.12.6774</ArticleId><ArticleId IdType="pmc">PMC22631</ArticleId><ArticleId IdType="pubmed">9618488</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Yafal AG, Lee YM, Hogle J, Chow M. 1994. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature. J Virol 68:3965&#x2013;3970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC236902</ArticleId><ArticleId IdType="pubmed">7514682</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert X, Gouet P. 2014. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res 42:W320&#x2013;W324. doi:10.1093/nar/gku316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku316</ArticleId><ArticleId IdType="pmc">PMC4086106</ArticleId><ArticleId IdType="pubmed">24753421</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>